BeOne Medicines Statistics
Total Valuation
BeOne Medicines has a market cap or net worth of $33.83 billion. The enterprise value is $32.10 billion.
Important Dates
The last earnings date was Wednesday, August 6, 2025, before market open.
| Earnings Date | Aug 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BeOne Medicines has 110.03 million shares outstanding. The number of shares has increased by 2.33% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 110.03M |
| Shares Change (YoY) | +2.33% |
| Shares Change (QoQ) | +1.25% |
| Owned by Insiders (%) | 4.62% |
| Owned by Institutions (%) | 44.95% |
| Float | 67.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 94.89 |
| PS Ratio | 7.20 |
| Forward PS | 3.62 |
| PB Ratio | 8.96 |
| P/TBV Ratio | 9.13 |
| P/FCF Ratio | 138.19 |
| P/OCF Ratio | 59.23 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 405.61, with an EV/FCF ratio of 131.12.
| EV / Earnings | n/a |
| EV / Sales | 7.04 |
| EV / EBITDA | 405.61 |
| EV / EBIT | n/a |
| EV / FCF | 131.12 |
Financial Position
The company has a current ratio of 1.95, with a Debt / Equity ratio of 0.27.
| Current Ratio | 1.95 |
| Quick Ratio | 1.65 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | 8.77 |
| Debt / FCF | 4.19 |
| Interest Coverage | -4.70 |
Financial Efficiency
Return on equity (ROE) is -4.98% and return on invested capital (ROIC) is -1.37%.
| Return on Equity (ROE) | -4.98% |
| Return on Assets (ROA) | -1.06% |
| Return on Invested Capital (ROIC) | -1.37% |
| Return on Capital Employed (ROCE) | -2.48% |
| Revenue Per Employee | $414,727 |
| Profits Per Employee | -$16,149 |
| Employee Count | 11,000 |
| Asset Turnover | 0.76 |
| Inventory Turnover | 1.59 |
Taxes
In the past 12 months, BeOne Medicines has paid $114.44 million in taxes.
| Income Tax | 114.44M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +61.82% in the last 52 weeks. The beta is 0.27, so BeOne Medicines's price volatility has been lower than the market average.
| Beta (5Y) | 0.27 |
| 52-Week Price Change | +61.82% |
| 50-Day Moving Average | 272.49 |
| 200-Day Moving Average | 235.62 |
| Relative Strength Index (RSI) | 63.59 |
| Average Volume (20 Days) | 460,143 |
Short Selling Information
The latest short interest is 1.77 million, so 1.61% of the outstanding shares have been sold short.
| Short Interest | 1.77M |
| Short Previous Month | 1.62M |
| Short % of Shares Out | 1.61% |
| Short % of Float | 2.64% |
| Short Ratio (days to cover) | 4.36 |
Income Statement
In the last 12 months, BeOne Medicines had revenue of $4.56 billion and -$177.64 million in losses. Loss per share was -$1.66.
| Revenue | 4.56B |
| Gross Profit | 3.81B |
| Operating Income | -101.51M |
| Pretax Income | n/a |
| Net Income | -177.64M |
| EBITDA | 79.15M |
| EBIT | -101.51M |
| Loss Per Share | -$1.66 |
Full Income StatementBalance Sheet
The company has $2.76 billion in cash and $1.03 billion in debt, giving a net cash position of $1.73 billion or $15.73 per share.
| Cash & Cash Equivalents | 2.76B |
| Total Debt | 1.03B |
| Net Cash | 1.73B |
| Net Cash Per Share | $15.73 |
| Equity (Book Value) | 3.77B |
| Book Value Per Share | 34.32 |
| Working Capital | 2.10B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $571.21 million and capital expenditures -$326.37 million, giving a free cash flow of $244.84 million.
| Operating Cash Flow | 571.21M |
| Capital Expenditures | -326.37M |
| Free Cash Flow | 244.84M |
| FCF Per Share | $2.23 |
Full Cash Flow StatementMargins
Gross margin is 83.51%, with operating and profit margins of -2.23% and -3.89%.
| Gross Margin | 83.51% |
| Operating Margin | -2.23% |
| Pretax Margin | -1.39% |
| Profit Margin | -3.89% |
| EBITDA Margin | 1.74% |
| EBIT Margin | -2.23% |
| FCF Margin | 5.37% |
Dividends & Yields
BeOne Medicines does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.33% |
| Shareholder Yield | -2.33% |
| Earnings Yield | -0.53% |
| FCF Yield | 0.72% |
Analyst Forecast
The average price target for BeOne Medicines is $335.78, which is 9.19% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $335.78 |
| Price Target Difference | 9.19% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 75.41% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BeOne Medicines has an Altman Z-Score of 4.71 and a Piotroski F-Score of 5.
| Altman Z-Score | 4.71 |
| Piotroski F-Score | 5 |